Comparative Pharmacology
Head-to-head clinical analysis: METAHYDRIN versus RENESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METAHYDRIN versus RENESE.
METAHYDRIN vs RENESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metahydrin (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing excretion of water, sodium, chloride, and potassium.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
Oral, 50-100 mg once daily. Maximum 200 mg/day.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
None Documented
None Documented
18-30 hours (clinically relevant for once-daily dosing in hypertension; prolonged in renal impairment)
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Renal: 30% (fecal: 70% as unabsorbed drug, primarily biliary elimination; <1% unchanged in urine)
Renal: ~85% unchanged; fecal: ~15% (via bile).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic